Vironova Biosafety

Vironova Biosafety

Vironova Biosafety is a contract research organization (CRO) specialized in performing viral clearance studies for biological drugs. The purpose of viral clearance studies is to evaluate the ability of a particular purification process used in pharmaceutical production to disable or eliminate potential viral contamination. 

It is mandatory to perform viral clearance validation on pharmaceutical purification processes where material of human or animal origin is used.

Vironova Biosafety is the only Nordic CRO that conducts these studies in BSLII and BSLIII certified cell and virus laboratories and in compliance with good laboratory practices (GLP).  Services range from early R&D to market release.

Our office and laboratories are located in central Stockholm. Our customers can be found worldwide. 

Experienced and well-connected

The average experience per person in the team is 24 years and the parent company Vironova AB has 6 of the 10 largest pharma companies as clients.

Lennart Lindqvist is Director Vironova Biosafety. Lennart holds a B.Sc. from the University of Gothenburg and more than 19 years of extensive sales and marketing experience in the pharmaceutical industry. Prior to joining Vironova, he has held positions as Director Sales Operations, Nordics at Alexion Pharma Nordics AB and Associate Sales and Marketing Director, Nordics at Shire Sweden AB. 

You can contact him directly by e-mail: lennart.lindqvist@vironova.com

Vironova Biosafety is part of the Vironova group of companies

Vironova Biosafety is part of the Vironova group

You can read more about Vironova AB and the other daughter companies here. Use your browser back button to return to the Biosafety web site. 

Sample description (optional)

Analysis objective (optional)

Services

Study Proposal Form

Please fill out the following information with as much detail as you can, in order for us to provide you with an accurate quote as soon as possible.

* - Compulsory fields
What is the nature of the product
If relevant, where will the product be marketed
Should the study be performed in compliance with GLP
Should the study be performed in duplicate
Will a representative from your company be present during the testing
Process steps to be tested Model viruses Processing time Number of points for sampling If representative(s) will be present, please specify for which step(s)
Vironova Biosafety
Thank you for your interest.